Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

• Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. • Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. • Baricitinb reduces SARS-CoV-2 viral burden detected by na...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Infect
Main Authors: Cantini, Fabrizio, Niccoli, Laura, Nannini, Carlotta, Matarrese, Daniela, Natale, Massimo Edoardo Di, Lotti, Pamela, Aquilini, Donatella, Landini, Giancarlo, Cimolato, Barbara, Pietro, Massimo Antonio Di, Trezzi, Michele, Stobbione, Paolo, Frausini, Gabriele, Navarra, Assunta, Nicastri, Emanuele, Sotgiu, Giovanni, Goletti, Delia
Formato: Artigo
Idioma:Inglês
Publicado: The British Infection Association. Published by Elsevier Ltd. 2020
Assuntos:
Letter to the Editor
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7313480/
https://ncbi.nlm.nih.gov/pubmed/32592703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jinf.2020.06.052
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares